site map  

QUESTIONS?

+1 (802) 878-1777

hti@haemtech.com

ORDERING

Human Proteins

Bovine Proteins

Mouse Proteins

Other Species

Inhibitors

Substrates

Antibodies

Sample Collection Tubes

Deficient Plasmas

Assay Kits

Pricing

HOME PAGE

QUESTIONS?

+1 (802) 878-1777

hti@haemtech.com

β-Thromboglobulin 

DOMAIN STRUCTURE OF ß-THROMBOGLOBULIN The domain structure of the β-thromboglobulin monomer is represented. The β-thromboglobulin monomer is an 8,800 molecular weight peptide which is derived via NH₂-terminal proteolysis of a precursor molecule LAPF-4 (low affinity platelet factor-4). Although the COOH-terminal domain of β-thromboglobulin is characterized by a clustering of basic lysine residues, the affinity of b-thromboglobulin for heparin is significantly weaker than that of platelet factor-4. In its native state, β-thromboglobulin is a homotetramer consisting of four, identical, noncovalently-associated peptide chains.

PURCHASING AND PRODUCT INFORMATION

Catalog Number HBTG-0210	Description Human β-Thromboglobulin	Size 100 µg	Formulation 25 mM Hepes, 150 mM NaCl, pH 7.4
Storage -80oC	Purity >95% by SDS-PAGE	Activity Determination N/A	Shelf Life (properly stored) 12 months
	Sample Gel Information: Gel: Novex 4-12% Bis-Tris Load: Human Beta Thromboglobulin, 1 µg per lane Buffer: MES Standard:  SeeBluePlus 2; Myosin (188 kDa), Phosphorylase B (98 kDa), BSA (62 kDa), Glutamic Dehydrogenase (49 kDa), Alcohol Dehydrogenase (38 kDa), Carbonic Anhydrase (28 kDa), Myoglobin Red (17 kDa), Lysozyme (14 kDa), Aprotinin (6 kDa), Insulin, B chain (3 kDa).
U.S. Pricing	Product inquiry	SAMPLE DATA SHEET	ORDER NOW!

Overview of β-Thromboglobulin

β-thromboglobulin (b-TG), is a low molecular weight, heparin-binding, platelet-derived protein (1). It is similar to platelet factor-4 (PF-4) in that it is localized within the platelet alpha-granule at levels reported to range from 8.1-24.2 µg per 109 platelets (2,3). The relative concentration of β-TG in platelets exceeds that of plasma by 260,000-fold (4) making β-TG a convenient marker of platelet activation. Structurally, β-TG is analogous to PF-4 in that, in its native state, β-TG is a tetramer (1) consisting of four identical 8800 molecular weight peptide chains (5). In contrast to PF-4, β-TG exhibits a lower affinity for heparin and also exists as a larger molecular weight species known as "low affinity PF-4" (LAPF-4) (2). β-TG is derived from the proteolytic removal of four NH₂-terminal amino acid residues from a LAPF-4 (6,7). Immunological screening of partially fractionated supernatant from activated platelets revealed a highly basic form of β-TG distinct from LAPF-4 (7). This basic β-TG species, termed platelet basic protein (PBP), was subsequently isolated (8) and later concluded from immunological, peptide sequencing, and proteolytic processing studies to be a higher molecular weight precursor form of both LAPF-4 and β-TG (9,10). 

The physiological function of β-TG is not known. While early studies suggested that the precursor forms of β-TG were mitogenic for mouse fibroblasts (8,11), it was later concluded that this activity was due to growth factor contamination (10). β-TG has also been reported to inhibit prostacyclin-I₂ production by endothelial cells (12), however, the relevance of this effect has been called into question (13,14). The chemotactic activity of platelet alpha-granule proteins for human fibroblasts has been attributed to both PF-4 and β-TG (15). 

Human β-TG is prepared from the supernatant of activated platelets by heparin-agarose affinity chromatography and gel filtration (1,2). The purified protein is supplied in 25 mM Hepes, 150 mM NaCl pH 7.4 and should be stored at -80°C. Purity is assessed by SDS-PAGE analysis. 

Properties of β-Thromboglobulin

*calculated based upon amino acid sequence and molecular weight

PURCHASING AND PRODUCT INFORMATION

References 

1. Moore, S., et al., Biochim. Biophys. Acta, 379, 360 (1975). 
2. Rucinski, B., et al., Blood, 53, 47 (1979). 
3. Kaplan, K.L., et al., Blood, 53, 604 (1979). 
4. George, J.N., Blood, 76, 859 (1990). 
5. Begg, S., et al., Biochemistry, 17, 1739 (1978). 
6. Holt, J.C. and Niewiarowski, S., Biochim. Biophys. Acta, 632, 284 (1980). 
7. Niewiarowski, S., et al., Blood, 55, 453 (1980). 
8. Paul, D., et al., Proc. Natl. Acad. Sci. USA, 77, 5914 (1980). 
9. Varma, K.G., et al., Biochim. Biophys. Acta, 701, 7 (1982). 
10. Holt, J.C., et al., Biochemistry, 25, 1988 (1986). 
11. Niewiarowski, S. and Paul, D., in Platelets in Biology and Pathology, Vol. 2, pp. 91-106, (Gordon, J.L. ed.) Elsevier/North-Holland Biomedical Press (1981). 
12. Hope, W., et al., Nature, 282, 210 (1979). 
13. Ager, A. and Gordon, J.L., Thromb. Res., 24, 95 (1981). 
14. Poggi, A. et al., Proc. Soc. Exp. Biol. Med., 172, 543 (1983). 
15. Senior, R.M., et al., J. Cell. Biol., 96, 382 (1983).